PT-141 (bremelanotide) dosage: the one approved dose, and how community use departs from it

Most peptides we cover have no approved dose at all, so “dosage” means whatever a trial happened to use. PT-141 is the rare exception. As bremelanotide, it carries a genuine FDA approval under the brand Vyleesi, which means there is a real, regulator-sanctioned dose with a precise schedule behind it. The catch is that the approval is narrow, and almost everything sold and discussed as “PT-141” online operates outside it. For what the molecule actually does, start with the PT-141 evidence monograph.

The one approved dose: 1.75 mg, subcutaneous, on demand

The Vyleesi label is specific. The approved dose is 1.75 mg injected under the skin (the abdomen or thigh), taken as needed at least 45 minutes before anticipated sexual activity.^[1] It is not a daily medication and not something you titrate upward; it is a single, fixed, on-demand dose. The label also sets hard ceilings: no more than one dose in any 24-hour period, and no more than eight doses per month.^[1]Those limits aren’t arbitrary — they exist because the drug’s side effects scale with how much and how often you take it.

Why the dose is fixed, not titrated

Bremelanotide is a melanocortin-receptor agonist that acts centrally, in the brain, rather than on blood vessels.^[2] The 1.75 mg figure came out of a clinical development program that tested bremelanotide against placebo and settled on a single on-demand dose as the best balance of effect and tolerability.^[3] Pushing the dose higher doesn’t cleanly buy more benefit; it mostly buys more nausea and a larger blood-pressure swing. That is the logic behind a fixed dose with a 24-hour and monthly cap rather than an open-ended “take more if it isn’t working” approach.

How community and compounded “PT-141” dosing differs

Most online PT-141 use looks nothing like the Vyleesi schedule. It is widely sold as a research chemical or compounded vial and used by men and by people seeking a general “libido” effect — all uses the approval does not cover. Community dosing protocols are typically reconstituted from powder and dosed by the milligram in ways that often run higher than 1.75 mg, with no fixed schedule and no manufacturer to set a ceiling. None of that has been validated: there is no approved dose for men, no approved dose for general libido use, and no quality control guaranteeing the milligrams in an unregulated vial match the label.^[3] Reconstituting and measuring an injectable peptide accurately is its own source of error — see our reconstitution calculator for why the math is easy to get wrong. The honest summary is that “higher than 1.75 mg, taken however the forum suggests” is a guess wearing the borrowed credibility of a real approval.

The dose-related cautions worth knowing

Three effects are documented in the clinical program and the label, and all three track with dose.^[4][1] Nausea is the most common and was the leading reason people stopped treatment; it tends to be worst with the first dose.^[4] Bremelanotide also causes a transient increase in blood pressure (with a small drop in heart rate) after each dose, which is exactly why it is not recommended for people with uncontrolled hypertension or known cardiovascular disease, and why the once-daily cap exists.^[4] Finally, repeated dosing can cause focal hyperpigmentation — patches of darker skin, including on the face and gums — that may not fully reverse, a direct consequence of acting on melanocortin pathways.^[4] Taking more, or more often, than the approved schedule turns up the volume on all three. Longer-term use was also followed in an extension study, which is the closest thing to data on what repeated dosing looks like over time.^[5]

Route and timing matter as much as the number

It is worth stressing that the approved product is subcutaneous and on demand — injected, not sprayed or swallowed, and timed roughly 45 minutes ahead.^[1]That timing isn’t optional flavor; it reflects how long the drug takes to act centrally. An earlier intranasal formulation of bremelanotide was abandoned in development over blood-pressure increases, a reminder that route changes the safety picture and that the approved route and schedule were chosen for a reason.^[3] Any “PT-141” used by a different route or on a different timetable is, again, outside what was studied.

The honest bottom line

If you reduce PT-141 dosing to what the evidence actually supports: 1.75 mg subcutaneously, as needed at least 45 minutes before activity, capped at one dose per day and eight per month, in premenopausal women with HSDD.^[1][3] That is the only validated dose, and it comes with real, dose-dependent downsides led by nausea, a blood-pressure rise, and possible skin darkening. Everything beyond it — men, general libido use, higher gray-market doses, alternative routes — is unstudied territory wearing the label of something that was carefully studied. A decision about whether and how to use it belongs with a clinician who can screen for the cardiovascular cautions, not a dosing thread. See also how PT-141 stacks up on evidence in our peptide evidence matrix.